PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings

Core Insights - PharmaTher has launched KetAImine™, an AI-driven platform aimed at repurposing ketamine for new therapeutic indications and combination therapies, facilitating earlier partnerships and expediting NDA filings through the 505(b)(2) pathway [2][3][8] Company Overview - PharmaTher Holdings Ltd. is a specialty life sciences company focused on maximizing the pharmaceutical potential of ketamine, with a newly formed Digital Health AI division that includes the KetAImine™ platform and KetaVault™ data repository [2][9] Platform Features - KetAImine™ integrates real-world data, clinical findings, and proprietary data from KetaVault™ to identify new uses and combinations of ketamine, enhancing efficacy and safety across various therapeutic areas [3][4] - The platform employs advanced natural language processing and analytics to structure clinical data, estimate real-world effects, and identify potential responder subpopulations [4][6] Strategic Goals - The platform aims to create a scalable pipeline for NDA submissions and partnerships, focusing on areas such as psychiatry, CNS disorders, addiction, and supportive oncology [3][8] - Near-term milestones include finalizing priority programs and initiating FDA interactions, with plans to announce collaborations and file new intellectual property throughout 2026 [7][8] Data Repository - KetaVault™ consolidates various datasets related to diseases like Parkinson's and ALS, as well as formulation initiatives, providing a standardized resource for the KetAImine™ platform [6]